Sinopharm Accord, a subsidiary of Sinopharm Group Co. Ltd., released its unaudited results for the third quarter of 2026, showing a solid rebound in profitability despite a largely flat nine-month top line.

Quarterly Highlights (3Q 2026) • Revenue reached RMB 18.80 billion, up 2.57% year on year, reversing the decline recorded in the first half. • Net profit attributable to shareholders rose 18.91% to RMB 346.29 million, while profit after non-recurring items climbed 23.47% to RMB 345.90 million. • Basic and diluted EPS improved 18.75% to RMB 0.57. • Weighted average ROE increased by 0.23 percentage point to 1.82%.

Year-to-Date Performance (Jan–Sep 2026) • Revenue slipped marginally by 0.11% to RMB 55.07 billion. • Net profit attributable to shareholders declined 0.48% to RMB 952.49 million, though profit after non-recurring items inched up 2.36% to RMB 944.78 million. • Operating profit stood at RMB 1.33 billion (-0.47% YoY), while total profit was broadly stable at RMB 1.32 billion (-0.05% YoY). • Net operating cash outflow widened 8.60% to RMB 502.89 million. • Year-to-date EPS remained at RMB 1.56; weighted average ROE eased 0.26 percentage point to 5.03%.

Segment Breakdown 1. Distribution – Revenue: RMB 40.57 billion (-0.07% YoY) – Net profit: RMB 754.00 million (+4.28% YoY) The segment narrowed its revenue contraction and restored profit growth by focusing on core operations and market expansion.

2. Retail (Guoda Drugstore) – Revenue: RMB 15.23 billion (+0.05% YoY) – Net profit: RMB 27.00 million (+105.08% YoY) Performance benefited from product-mix optimization, store network adjustments and stringent expense control, leading to a doubling of net profit.

Balance Sheet Snapshot (30 Sep 2026) • Total assets amounted to RMB 48.90 billion, down 0.39% from end-2025. • Equity attributable to shareholders increased 3.28% to RMB 19.22 billion, reflecting profit retention and a 1-for-10 bonus share issuance completed in June 2026.

Outlook Management reiterated its intention to maintain strategic focus amid ongoing industry reforms, citing plans to enhance supply-chain efficiency, pursue incremental markets and refine product portfolios to sustain profitability and mitigate policy-driven pricing pressures.

The disclosed figures are unaudited and extracted from Sinopharm Accord’s third-quarter 2026 report filed with the Shenzhen Stock Exchange on 30 October 2026.